Source:http://linkedlifedata.com/resource/pubmed/id/19422335
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-5-8
|
| pubmed:abstractText |
Different strategies appear to improve the success in treatment of antibody-mediated rejection (AMR), although no one best method has yet emerged. The objective of this study was to compare the efficacy of the combination of Plasmapheresis/intravenous immunoglobulin (IVIg)/anti-CD20-based regimes versus high-dose IVIg alone in the treatment of AMR. Group A (12 patients) was treated with high-dose IVIg between January 2000 and December 2003; group B (12 patients) was treated by Plasmapheresis/IVIg/anti-CD20 between January 2004 and December 2005. Graft survival at 36 months was 91.7% in group B versus 50% in group A (p = 0.02). Donor-specific human leukocyte antigens (DSA) levels detected by Luminex single antigen (Luminex SA) and ELISA, 3 months postrejection are significantly lower in group B than in group A: DSA ELISA class 2 score 6-8 (p = 0.02), DSA mean intensity of fluorescence (MFI) max (p = 0.009) and DSA mean MFI (p = 0.0004). The persistence of elevated DSA levels posttreatment is more frequent in patients with graft loss as compared to those with preserved renal function: score 6-8 on ELISA (p = 0.04); mean MFI (p = 0.00009) and MFImax (p = 0.018). We conclude that: (1) high dose IVIg alone is inferior to Plasmapheresis/IVIg/anti-CD20 as therapy for AMR and (2)DSA postrejection can be quantified using solid phase assays, showing that 3 months after AMR, DSA levels are higher in patients with graft loss.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-B Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins, Intravenous,
http://linkedlifedata.com/resource/pubmed/chemical/Isoantibodies
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1600-6143
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1099-107
|
| pubmed:meshHeading |
pubmed-meshheading:19422335-Adolescent,
pubmed-meshheading:19422335-Adult,
pubmed-meshheading:19422335-Antibody Formation,
pubmed-meshheading:19422335-Antigens, CD20,
pubmed-meshheading:19422335-B-Lymphocytes,
pubmed-meshheading:19422335-Biopsy,
pubmed-meshheading:19422335-Combined Modality Therapy,
pubmed-meshheading:19422335-Female,
pubmed-meshheading:19422335-Glomerulosclerosis, Focal Segmental,
pubmed-meshheading:19422335-Graft Rejection,
pubmed-meshheading:19422335-HLA Antigens,
pubmed-meshheading:19422335-HLA-A Antigens,
pubmed-meshheading:19422335-HLA-B Antigens,
pubmed-meshheading:19422335-Histocompatibility Testing,
pubmed-meshheading:19422335-Humans,
pubmed-meshheading:19422335-Immunoglobulins, Intravenous,
pubmed-meshheading:19422335-Isoantibodies,
pubmed-meshheading:19422335-Kidney Transplantation,
pubmed-meshheading:19422335-Male,
pubmed-meshheading:19422335-Middle Aged,
pubmed-meshheading:19422335-Plasmapheresis,
pubmed-meshheading:19422335-T-Lymphocytes,
pubmed-meshheading:19422335-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.
|
| pubmed:affiliation |
Saint-Louis Hospital, Nephrology and Kidney Transplantation, Paris, France. carmen.lefaucheur@wanadoo.fr
|
| pubmed:publicationType |
Journal Article
|